In January 2021, JJDC invested in Paige.AI, an AI-based digital pathology company. The company’s Paige Prostate, which analyzes slides of biopsied prostate tissue aiming to spot the hallmarks of malignant cells, is the first FDA-approved AI in pathology.
Paige’s digital pathology technology leverages petabytes of data into clinical grade AI for cancer diagnostics, and computational biomarkers in oncology and beyond. By successfully unlocking insights from patient samples, pathologists, care teams and researchers may be able to make decisions more confidently and efficiently to optimize treatment outcomes.
The investment through JJDC aligns with one of Janssen’s key goals, which is to extend the time without metastases and maintain the quality of life for people who have received a diagnosis of prostate cancer, so that we can ensure the best outcomes for them.